autologous platelets

Cell therapyexperimental

Clinical trial activity

24 trials · 50 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
10
Phase 3
4
Phase 4
4

Earliest trial started Jul 1, 2003 (NCT00074763)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • PlateletTissue restoration

    tissue restoration - platelet

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • autologous platelets

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07064954Phase 2/Phase 3 (Phase 3)Sep 1, 2025University of Toronto
NCT05796557Phase 4Nov 13, 2023Columbia University, Cornell University, Duke University, Emory University, Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), University of Iowa, University of Rochester, University of Utah, University of Wisconsin, Virginia Commonwealth University, Yale University
NCT06095648N/AOct 28, 2023Health Research Board, Ireland, Irish Blood Transfusion Service, National Maternity Hospital, Ireland, National University of Ireland
NCT05293106Phase 4Jul 5, 2022Cornell University
NCT04915287Phase 4Jun 6, 2021People's Liberation Army of China
NCT05111028Phase 1/Phase 2 (Phase 2)Nov 20, 2020Bloodworks Northwest, Department of Defense
NCT06535360Phase 4Sep 1, 2020University of Maryland
NCT03968484N/AAug 1, 2019University of Tuebingen
NCT03712618Phase 2Jun 10, 2019National Institutes of Health (NIH)
NCT04564651N/AMay 1, 2019Southern Medical University
NCT03787927Phase 1/Phase 2 (Phase 2)Dec 3, 2018Bloodworks Northwest, National Blood Foundation
NCT03561909N/AApr 17, 2018Fraunhofer, Fraunhofer-Institute of Toxicology and Experimental Medicine, German Red Cross, Larix A/S, Prophylix Pharma AS
NCT04807621Phase 2Mar 14, 2018University of Gothenburg
NCT03195010Phase 2Jun 9, 2017National Cancer Institute (NCI), University of Washington
NCT03090919N/AJan 3, 2017University of Kentucky
NCT02653443Phase 2Dec 31, 2015Cerus Corporation
NCT01615146N/AJun 30, 2012Canadian Blood Services, Canadian Institutes of Health Research (CIHR), University of Ottawa
NCT01248351Phase 2Nov 1, 2010CSL Behring, Medical University of Graz, Novo Nordisk
NCT00937053Phase 2Jun 30, 2009St. Justine's Hospital
NCT00672672Phase 3Feb 1, 2009University of Nebraska
Showing 20 of 24 trials
Page 1 / 2

Organizations

Research & Development (50)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bloodworks NorthwestAcademic/Hospital2212018
Cornell UniversityAcademic/Hospital2112022
Aix-University of MarseilleAcademic/Hospital1012007
Canadian Blood ServicesAcademic/Hospital1012012
Canadian Institutes of Health Research (CIHR)Academic/Hospital1012012
Cerus CorporationFor profit1112015
Columbia UniversityAcademic/Hospital1012023
CSL BehringFor profit1012010
Department of DefenseGovernment1012020
Duke UniversityAcademic/Hospital1012023
Emory UniversityAcademic/Hospital1012023
FraunhoferFor profit1012018
Fraunhofer-Institute of Toxicology and Experimental MedicineAcademic/Hospital1012018
German Red CrossAcademic/Hospital1012018
Ghent UniversityAcademic/Hospital1112008
Health Research Board, IrelandAcademic/Hospital1012023
Irish Blood Transfusion ServiceAcademic/Hospital1012023
Johns Hopkins UniversityAcademic/Hospital1012023
Johnson and JohnsonFor profit1012008
Larix A/SFor profit1012018
50 organizations
Page 1 / 3